Cargando…
Quelle chimiothérapie dans les tumeurs phyllodes métastatiques du sein? rapport de cas
Phyllodes tumors (PT) of the breast are rare. They can be benign, borderline or malignant. Malignant forms account for 20-30% of PTs, with distant metastases in 10-26% of cases. Chemotherapy is one of the main therapeutic weapons for metastatic phyllodes tumors (MPTs). We here report four cases of M...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The African Field Epidemiology Network
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643797/ https://www.ncbi.nlm.nih.gov/pubmed/36415336 http://dx.doi.org/10.11604/pamj.2022.42.293.20377 |
_version_ | 1784826597578113024 |
---|---|
author | Kaikai, Imane Ait Bourhafour, Mouna Haffadi, Meriem Bouchbika, Zineb Benchakroune, Nadia Jouhadi, Hassan Tawfiq, Nezha Sahraoui, Souha Benider, Abdellatif |
author_facet | Kaikai, Imane Ait Bourhafour, Mouna Haffadi, Meriem Bouchbika, Zineb Benchakroune, Nadia Jouhadi, Hassan Tawfiq, Nezha Sahraoui, Souha Benider, Abdellatif |
author_sort | Kaikai, Imane Ait |
collection | PubMed |
description | Phyllodes tumors (PT) of the breast are rare. They can be benign, borderline or malignant. Malignant forms account for 20-30% of PTs, with distant metastases in 10-26% of cases. Chemotherapy is one of the main therapeutic weapons for metastatic phyllodes tumors (MPTs). We here report four cases of MPTs of the breast managed at The Mohammed VI Center For Cancers Treatment in Casablanca from January 2015 to December 2017. The average age of patients ranged from 25 to 45 years. The mode of revelation was represented, in the majority of cases, by the occurrence of a huge breast mass and in all patients the histological diagnosis was based on the examination of mastectomy specimen. Three patients had lung metastases, two had axillary lymph-node metastases, two had bone metastases and only one had liver metastases. All patients received chemotherapy. Doxorubicin monotherapy and doxorubicin-ifosfamide (AI) were used. Only one patient had a very favorable outcome, with radiologic complete response after 3 AI regimens. MPTs of the breast have a poor prognosis. The role of systemic chemotherapy is to be defined, especially since there are no data available on optimal chemotherapy regimen. |
format | Online Article Text |
id | pubmed-9643797 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The African Field Epidemiology Network |
record_format | MEDLINE/PubMed |
spelling | pubmed-96437972022-11-21 Quelle chimiothérapie dans les tumeurs phyllodes métastatiques du sein? rapport de cas Kaikai, Imane Ait Bourhafour, Mouna Haffadi, Meriem Bouchbika, Zineb Benchakroune, Nadia Jouhadi, Hassan Tawfiq, Nezha Sahraoui, Souha Benider, Abdellatif Pan Afr Med J Case Report Phyllodes tumors (PT) of the breast are rare. They can be benign, borderline or malignant. Malignant forms account for 20-30% of PTs, with distant metastases in 10-26% of cases. Chemotherapy is one of the main therapeutic weapons for metastatic phyllodes tumors (MPTs). We here report four cases of MPTs of the breast managed at The Mohammed VI Center For Cancers Treatment in Casablanca from January 2015 to December 2017. The average age of patients ranged from 25 to 45 years. The mode of revelation was represented, in the majority of cases, by the occurrence of a huge breast mass and in all patients the histological diagnosis was based on the examination of mastectomy specimen. Three patients had lung metastases, two had axillary lymph-node metastases, two had bone metastases and only one had liver metastases. All patients received chemotherapy. Doxorubicin monotherapy and doxorubicin-ifosfamide (AI) were used. Only one patient had a very favorable outcome, with radiologic complete response after 3 AI regimens. MPTs of the breast have a poor prognosis. The role of systemic chemotherapy is to be defined, especially since there are no data available on optimal chemotherapy regimen. The African Field Epidemiology Network 2022-08-18 /pmc/articles/PMC9643797/ /pubmed/36415336 http://dx.doi.org/10.11604/pamj.2022.42.293.20377 Text en Copyright: Imane Ait Kaikai et al. https://creativecommons.org/licenses/by/4.0/The Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Kaikai, Imane Ait Bourhafour, Mouna Haffadi, Meriem Bouchbika, Zineb Benchakroune, Nadia Jouhadi, Hassan Tawfiq, Nezha Sahraoui, Souha Benider, Abdellatif Quelle chimiothérapie dans les tumeurs phyllodes métastatiques du sein? rapport de cas |
title | Quelle chimiothérapie dans les tumeurs phyllodes métastatiques du sein? rapport de cas |
title_full | Quelle chimiothérapie dans les tumeurs phyllodes métastatiques du sein? rapport de cas |
title_fullStr | Quelle chimiothérapie dans les tumeurs phyllodes métastatiques du sein? rapport de cas |
title_full_unstemmed | Quelle chimiothérapie dans les tumeurs phyllodes métastatiques du sein? rapport de cas |
title_short | Quelle chimiothérapie dans les tumeurs phyllodes métastatiques du sein? rapport de cas |
title_sort | quelle chimiothérapie dans les tumeurs phyllodes métastatiques du sein? rapport de cas |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643797/ https://www.ncbi.nlm.nih.gov/pubmed/36415336 http://dx.doi.org/10.11604/pamj.2022.42.293.20377 |
work_keys_str_mv | AT kaikaiimaneait quellechimiotherapiedanslestumeursphyllodesmetastatiquesduseinrapportdecas AT bourhafourmouna quellechimiotherapiedanslestumeursphyllodesmetastatiquesduseinrapportdecas AT haffadimeriem quellechimiotherapiedanslestumeursphyllodesmetastatiquesduseinrapportdecas AT bouchbikazineb quellechimiotherapiedanslestumeursphyllodesmetastatiquesduseinrapportdecas AT benchakrounenadia quellechimiotherapiedanslestumeursphyllodesmetastatiquesduseinrapportdecas AT jouhadihassan quellechimiotherapiedanslestumeursphyllodesmetastatiquesduseinrapportdecas AT tawfiqnezha quellechimiotherapiedanslestumeursphyllodesmetastatiquesduseinrapportdecas AT sahraouisouha quellechimiotherapiedanslestumeursphyllodesmetastatiquesduseinrapportdecas AT beniderabdellatif quellechimiotherapiedanslestumeursphyllodesmetastatiquesduseinrapportdecas |